Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
相关临床试验
7
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
2
28.6%
终止
4
57.1%
撤回
1
14.3%
暂无批准数据
- Vor Biopharma reported updated Phase 1/2 VBP101 study results showing promising relapse-free survival data in AML/MDS patients, exceeding historical benchmarks. - Initial PK data for VCAR33ALLO demonstrated in vivo expansion at the lowest dose, with dose escalation planned, indicating potential efficacy. - The company is developing a new CD45 ADC program (VADC45) for conditioning regimens, offering a fast path to commercial development and partnership opportunities. - Analysts maintain an Outperform rating with a price target of US$11.00, citing significant upside potential from trem-cel and CD45-based depletion approaches.
- RemeGen's telitacicept demonstrated a 55% reduction in 24-hour urine protein-to-creatinine ratio at 39 weeks compared to placebo in a Phase 3 IgA nephropathy trial. - The multicenter, randomized, double-blind, placebo-controlled study involved 318 participants and successfully met its primary endpoint of reducing proteinuria. - RemeGen plans to submit a Biologics License Application to China's National Medical Products Administration for IgA nephropathy indication. - The positive results represent a significant advancement for patients with IgA nephropathy, a progressive kidney disease with limited treatment options.
